Business Description
IGEA Pharma NV
ISIN : NL0012768675
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | -10.04 | |||||
Debt-to-Equity | -0.48 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 17.8 | |||||
3-Year EPS without NRI Growth Rate | 23.9 | |||||
3-Year FCF Growth Rate | 74 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.25 | |||||
9-Day RSI | 47.32 | |||||
14-Day RSI | 48.33 | |||||
6-1 Month Momentum % | -80 | |||||
12-1 Month Momentum % | -98.68 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.16 | |||||
Quick Ratio | 0.16 | |||||
Cash Ratio | 0.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -137.8 | |||||
Shareholder Yield % | 18.25 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -467.54 | |||||
ROA % | -253.98 | |||||
ROIC % | -250.2 | |||||
ROC (Joel Greenblatt) % | -3953.06 | |||||
ROCE % | -400.62 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -0.07 | |||||
EV-to-EBITDA | -0.07 | |||||
EV-to-FCF | -1.95 | |||||
Earnings Yield (Greenblatt) % | -1428.57 | |||||
FCF Yield % | -118.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
IGEA Pharma NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.029 | ||
Beta | 0 | ||
Volatility % | 531.12 | ||
14-Day RSI | 48.33 | ||
14-Day ATR (€) | 0.000701 | ||
20-Day SMA (€) | 0.001475 | ||
12-1 Month Momentum % | -98.68 | ||
52-Week Range (€) | 0.0005 - 0.075 | ||
Shares Outstanding (Mil) | 337.03 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
IGEA Pharma NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
IGEA Pharma NV Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
IGEA Pharma NV Frequently Asked Questions
What is IGEA Pharma NV(FRA:3B5)'s stock price today?
When is next earnings date of IGEA Pharma NV(FRA:3B5)?
Does IGEA Pharma NV(FRA:3B5) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |